Artiva Biotherapeutics, Inc. Common Stock (ARTV) is a Healthcare · Biotechnology company listed on NASDAQ. Price $8.61 (+2.01%), Market cap $0.22B, 52-week low–high $1.47 ~ $9.10.
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2
Financial statements, price targets, institutional (13F) holdings and related news for Artiva Biotherapeutics, Inc. Common Stock are updated in real time on BlackAll Trade.
Artiva Biotherapeutics, Inc. Common Stock trades at $8.61 (+2.01%). Real-time quotes and charts are available on BlackAll Trade.
Artiva Biotherapeutics, Inc. Common Stock has a market cap of about $0.22B.
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its le